Co-authored publications with mentees

David A. Scheinberg, MD, PhD · 33 publications across 14 mentees

CSV Word

MD-PhD mentee

Challenges and solutions for therapeutic TCR-based agents.
Immunological reviews · 2023
DADavid A. ScheinbergSPStephanie PierreZEZita E H AretzZMZaki MolviPWPatrick Wallisch
PMID: 37455333PMCID: PMC11141734DOI31 citations
With Stephanie Pierre · MD-PhD Program (MD-PhD)
Host Interactions with Engineered T-cell Micropharmacies.
Cancer immunology research · 2023
DADavid A. ScheinbergSPStephanie PierreCMChristopher M BournePWPatrick WallischKVKristen Vogt+4 more →
PMID: 37379366PMCID: PMC10472090DOI4 citations
With Stephanie Pierre · MD-PhD Program (MD-PhD)
Host-cell Interactions of Engineered T cell Micropharmacies.
bioRxiv : the preprint server for biology · 2023
DADavid A. ScheinbergSPStephanie PierreCMChristopher M BournePWPatrick WallischKVKristen Vogt+4 more →
PMID: 37205431PMCID: PMC10187158DOI
With Stephanie Pierre · MD-PhD Program (MD-PhD)
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
Blood · 2023
DADavid A. ScheinbergSPStephanie PierreKKKeifer KurtzPWPatrick WallischSKShireen Khayat+2 more →
PMID: 36696633PMCID: PMC10163312DOI46 citations
With Stephanie Pierre · MD-PhD Program (MD-PhD)

PhD mentee

CD8 co-receptor modulates the specificity profile of the 1G4 TCR against NY-ESO-1.
Molecular therapy : the journal of the American Society of Gene Therapy · 2025
DADavid A. ScheinbergZEZita E H AretzHFHeather F Jones
PMID: 41058174PMCID: PMC12590357DOI
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
CD8 co-receptor modulates the specificity profile of the 1G4 TCR against NY-ESO-1.
Molecular therapy : the journal of the American Society of Gene Therapy · 2025
DADavid A. ScheinbergHFHeather F JonesZEZita E H Aretz
PMID: 41058174PMCID: PMC12590357DOI
With Heather Jones · Pharmacology (PhD) · Class of 2022
Metabolic engineering to facilitate anti-tumor immunity.
Cancer cell · 2025
DADavid A. ScheinbergPWPatrick WallischTSTanya SchildKPKaitlyn Pierpont
PMID: 40020672PMCID: PMC11929521DOI26 citations
With Patrick Wallisch · Pharmacology (PhD)
Metabolic engineering to facilitate anti-tumor immunity.
Cancer cell · 2025
DADavid A. ScheinbergKPKaitlyn PierpontTSTanya SchildPWPatrick Wallisch
PMID: 40020672PMCID: PMC11929521DOI26 citations
With Kaitlyn Pierpont · Pharmacology (PhD)
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
Science advances · 2025
DADavid A. ScheinbergKCKristen C VogtPCPedro C SilbermanQLQianqian LinJEJames E Han+1 more →
PMID: 39841845PMCID: PMC11753401DOI23 citations
With Kristen Vogt · Tri-I Program in Chemical Biology (PhD) · Class of 2024
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
Science advances · 2025
DADavid A. ScheinbergPCPedro C SilbermanKCKristen C VogtQLQianqian LinJEJames E Han+1 more →
PMID: 39841845PMCID: PMC11753401DOI23 citations
With Pedro Silberman · Pharmacology (PhD) · Class of 2023
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
Science advances · 2025
DADavid A. ScheinbergQLQianqian LinKCKristen C VogtPCPedro C SilbermanJEJames E Han+1 more →
PMID: 39841845PMCID: PMC11753401DOI23 citations
With Qianqian Lin · Molecular Biology (PhD)
Augmenting CAR T-cell Functions with LIGHT.
Cancer immunology research · 2024
DADavid A. ScheinbergWCWinson CaiJFJonathan F. KhanPAParwiz AbrahimiJHJohn H Healey+2 more →
PMID: 38959337PMCID: PMC11444887DOI4 citations
With Winson Cai · Pharmacology (PhD) · Class of 2024
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.
Theranostics · 2023
DADavid A. ScheinbergKKKeifer KurtzLELaura EiblerSQSarah QureshySKShireen Khayat+2 more →
PMID: 37908719PMCID: PMC10614694DOI23 citations
With Keifer Kurtz · Pharmacology (PhD)
Challenges and solutions for therapeutic TCR-based agents.
Immunological reviews · 2023
DADavid A. ScheinbergZEZita E H AretzZMZaki MolviSPStephanie PierrePWPatrick Wallisch
PMID: 37455333PMCID: PMC11141734DOI31 citations
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
Challenges and solutions for therapeutic TCR-based agents.
Immunological reviews · 2023
DADavid A. ScheinbergPWPatrick WallischZEZita E H AretzZMZaki MolviSPStephanie Pierre
PMID: 37455333PMCID: PMC11141734DOI31 citations
With Patrick Wallisch · Pharmacology (PhD)
Host Interactions with Engineered T-cell Micropharmacies.
Cancer immunology research · 2023
DADavid A. ScheinbergCMChristopher M BournePWPatrick WallischSPStephanie PierreKVKristen Vogt+4 more →
PMID: 37379366PMCID: PMC10472090DOI4 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Host Interactions with Engineered T-cell Micropharmacies.
Cancer immunology research · 2023
DADavid A. ScheinbergKKKeifer KurtzCMChristopher M BournePWPatrick WallischSPStephanie Pierre+4 more →
PMID: 37379366PMCID: PMC10472090DOI4 citations
With Keifer Kurtz · Pharmacology (PhD)
Host Interactions with Engineered T-cell Micropharmacies.
Cancer immunology research · 2023
DADavid A. ScheinbergKVKristen VogtCMChristopher M BournePWPatrick WallischSPStephanie Pierre+4 more →
PMID: 37379366PMCID: PMC10472090DOI4 citations
With Kristen Vogt · Tri-I Program in Chemical Biology (PhD) · Class of 2024
Host Interactions with Engineered T-cell Micropharmacies.
Cancer immunology research · 2023
DADavid A. ScheinbergPWPatrick WallischCMChristopher M BourneSPStephanie PierreKVKristen Vogt+4 more →
PMID: 37379366PMCID: PMC10472090DOI4 citations
With Patrick Wallisch · Pharmacology (PhD)
Host-cell Interactions of Engineered T cell Micropharmacies.
bioRxiv : the preprint server for biology · 2023
DADavid A. ScheinbergCMChristopher M BournePWPatrick WallischSPStephanie PierreKVKristen Vogt+4 more →
PMID: 37205431PMCID: PMC10187158DOI
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Host-cell Interactions of Engineered T cell Micropharmacies.
bioRxiv : the preprint server for biology · 2023
DADavid A. ScheinbergKKKeifer KurtzCMChristopher M BournePWPatrick WallischSPStephanie Pierre+4 more →
PMID: 37205431PMCID: PMC10187158DOI
With Keifer Kurtz · Pharmacology (PhD)
Host-cell Interactions of Engineered T cell Micropharmacies.
bioRxiv : the preprint server for biology · 2023
DADavid A. ScheinbergKVKristen VogtCMChristopher M BournePWPatrick WallischSPStephanie Pierre+4 more →
PMID: 37205431PMCID: PMC10187158DOI
With Kristen Vogt · Tri-I Program in Chemical Biology (PhD) · Class of 2024
Host-cell Interactions of Engineered T cell Micropharmacies.
bioRxiv : the preprint server for biology · 2023
DADavid A. ScheinbergPWPatrick WallischCMChristopher M BourneSPStephanie PierreKVKristen Vogt+4 more →
PMID: 37205431PMCID: PMC10187158DOI
With Patrick Wallisch · Pharmacology (PhD)
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
Blood · 2023
DADavid A. ScheinbergCMChristopher M BourneKKKeifer KurtzPWPatrick WallischSPStephanie Pierre+2 more →
PMID: 36696633PMCID: PMC10163312DOI46 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
Blood · 2023
DADavid A. ScheinbergKKKeifer KurtzPWPatrick WallischSPStephanie PierreSKShireen Khayat+2 more →
PMID: 36696633PMCID: PMC10163312DOI46 citations
With Keifer Kurtz · Pharmacology (PhD)
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
Blood · 2023
DADavid A. ScheinbergKCKristen C VogtKKKeifer KurtzPWPatrick WallischSPStephanie Pierre+2 more →
PMID: 36696633PMCID: PMC10163312DOI46 citations
With Kristen Vogt · Tri-I Program in Chemical Biology (PhD) · Class of 2024
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.
Blood · 2023
DADavid A. ScheinbergPWPatrick WallischKKKeifer KurtzSPStephanie PierreSKShireen Khayat+2 more →
PMID: 36696633PMCID: PMC10163312DOI46 citations
With Patrick Wallisch · Pharmacology (PhD)
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment.
Blood advances · 2022
DADavid A. ScheinbergCMChristopher M BourneZEZita E H AretzZMZaki MolviRSRon S Gejman+1 more →
PMID: 35561310PMCID: PMC9327544DOI16 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment.
Blood advances · 2022
DADavid A. ScheinbergZEZita E H AretzCMChristopher M BourneZMZaki MolviRSRon S Gejman+1 more →
PMID: 35561310PMCID: PMC9327544DOI16 citations
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies.
Blood · 2022
DADavid A. ScheinbergCBChristopher BourneZEZita E H AretzMLMichael LauMGMichael G Kharas
PMID: 35427421PMCID: PMC9412008DOI18 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies.
Blood · 2022
DADavid A. ScheinbergZEZita E H AretzCBChristopher BourneMLMichael LauMGMichael G Kharas
PMID: 35427421PMCID: PMC9412008DOI18 citations
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma.
The Journal of clinical investigation · 2022
DADavid A. ScheinbergCMChristopher M BourneAMAri M. MelnickWBWendy Béguelin
PMID: 35380993PMCID: PMC9106353DOI23 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Engineering CAR-T cells to activate small-molecule drugs in situ.
Nature chemical biology · 2021
DADavid A. ScheinbergCMChristopher M BourneKKKeifer KurtzBCBroderick C CorlessAYAaron Y Chang+2 more →
PMID: 34969970PMCID: PMC9152922DOI77 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Engineering CAR-T cells to activate small-molecule drugs in situ.
Nature chemical biology · 2021
DADavid A. ScheinbergAYAaron Y ChangCMChristopher M BourneKKKeifer KurtzBCBroderick C Corless+2 more →
PMID: 34969970PMCID: PMC9152922DOI77 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
Engineering CAR-T cells to activate small-molecule drugs in situ.
Nature chemical biology · 2021
DADavid A. ScheinbergKKKeifer KurtzCMChristopher M BourneBCBroderick C CorlessAYAaron Y Chang+2 more →
PMID: 34969970PMCID: PMC9152922DOI77 citations
With Keifer Kurtz · Pharmacology (PhD)
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.
Molecular therapy : the journal of the American Society of Gene Therapy · 2021
DADavid A. ScheinbergCMChristopher M BourneMMMegan M Dacek
PMID: 34217891PMCID: PMC8636170DOI17 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.
Molecular therapy : the journal of the American Society of Gene Therapy · 2021
DADavid A. ScheinbergMMMegan M DacekCMChristopher M Bourne
PMID: 34217891PMCID: PMC8636170DOI17 citations
With Megan Dacek · Pharmacology (PhD) · Class of 2021
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.
Oncoimmunology · 2021
DADavid A. ScheinbergCMChristopher M BourneZEZita E H Aretz
PMID: 34104540PMCID: PMC8158036DOI22 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.
Oncoimmunology · 2021
DADavid A. ScheinbergZEZita E H AretzCMChristopher M Bourne
PMID: 34104540PMCID: PMC8158036DOI22 citations
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.
Bioconjugate chemistry · 2021
DADavid A. ScheinbergMMMegan M DacekSMSarah M ChealNCNai-Kong Cheung
PMID: 33819023PMCID: PMC8284561DOI12 citations
With Megan Dacek · Pharmacology (PhD) · Class of 2021
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.
Frontiers in immunology · 2021
DADavid A. ScheinbergHFHeather F JonesZMZaki Molvi
PMID: 33569049PMCID: PMC7868419DOI26 citations
With Heather Jones · Pharmacology (PhD) · Class of 2022
CAR Chase: Where Do Engineered Cells Go in Humans?
Frontiers in oncology · 2020
DADavid A. ScheinbergMMMegan M Dacek
PMID: 33042849PMCID: PMC7518311DOI11 citations
With Megan Dacek · Pharmacology (PhD) · Class of 2021
Solving an MHC allele-specific bias in the reported immunopeptidome.
JCI insight · 2020
DADavid A. ScheinbergZEZita E H AretzKNKyeara N MackYBYang Bai
PMID: 32897882PMCID: PMC7566711DOI27 citations
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Cancers · 2020
DADavid A. ScheinbergCMChristopher M BourneMMMegan M DacekKKKeifer KurtzPCPedro C Silberman+3 more →
PMID: 32764348PMCID: PMC7465970DOI26 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Cancers · 2020
DADavid A. ScheinbergKKKeifer KurtzCMChristopher M BourneMMMegan M DacekPCPedro C Silberman+3 more →
PMID: 32764348PMCID: PMC7465970DOI26 citations
With Keifer Kurtz · Pharmacology (PhD)
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Cancers · 2020
DADavid A. ScheinbergKCKristen C VogtCMChristopher M BourneMMMegan M DacekKKKeifer Kurtz+3 more →
PMID: 32764348PMCID: PMC7465970DOI26 citations
With Kristen Vogt · Tri-I Program in Chemical Biology (PhD) · Class of 2024
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Cancers · 2020
DADavid A. ScheinbergMMMegan M DacekCMChristopher M BourneKKKeifer KurtzPCPedro C Silberman+3 more →
PMID: 32764348PMCID: PMC7465970DOI26 citations
With Megan Dacek · Pharmacology (PhD) · Class of 2021
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Cancers · 2020
DADavid A. ScheinbergPCPedro C SilbermanCMChristopher M BourneMMMegan M DacekKKKeifer Kurtz+3 more →
PMID: 32764348PMCID: PMC7465970DOI26 citations
With Pedro Silberman · Pharmacology (PhD) · Class of 2023
An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments.
Journal of proteomics · 2020
DADavid A. ScheinbergZEZita E H AretzRSRon S GejmanHFHeather F Jones
PMID: 32758705PMCID: PMC7484941DOI3 citations
With Zita Aretz · Physiology, Biophysics & Systems Biology (PhD) · Class of 2025
An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments.
Journal of proteomics · 2020
DADavid A. ScheinbergHFHeather F JonesZEZita E H AretzRSRon S Gejman
PMID: 32758705PMCID: PMC7484941DOI3 citations
With Heather Jones · Pharmacology (PhD) · Class of 2022
Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.
Cancer immunology research · 2020
DADavid A. ScheinbergAYAaron Y ChangRSRon S GejmanHFHeather F JonesCYClaire Y Oh+1 more →
PMID: 32184297PMCID: PMC7310334DOI35 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.
Cancer immunology research · 2020
DADavid A. ScheinbergCYClaire Y OhRSRon S GejmanHFHeather F JonesAYAaron Y Chang+1 more →
PMID: 32184297PMCID: PMC7310334DOI35 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019
Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.
Cancer immunology research · 2020
DADavid A. ScheinbergHFHeather F JonesRSRon S GejmanAYAaron Y ChangCYClaire Y Oh+1 more →
PMID: 32184297PMCID: PMC7310334DOI35 citations
With Heather Jones · Pharmacology (PhD) · Class of 2022
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Cancer discovery · 2020
DADavid A. ScheinbergAYAaron Y ChangMTMatt TeaterLFLorena FontanHYHsia-Yuan Ying+3 more →
PMID: 31915197PMCID: PMC7275250DOI146 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
Cancer immunology research · 2019
DADavid A. ScheinbergCBChristopher BourneCYClaire Y OhMMMegan M DacekEJElliott J Brea+1 more →
PMID: 31540894PMCID: PMC6891198DOI40 citations
With Christopher Bourne · Immunology & Microbial Pathogenesis (PhD) · Class of 2023
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
Cancer immunology research · 2019
DADavid A. ScheinbergAYAaron Y ChangCYClaire Y OhCBChristopher BourneMMMegan M Dacek+1 more →
PMID: 31540894PMCID: PMC6891198DOI40 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
Cancer immunology research · 2019
DADavid A. ScheinbergCYClaire Y OhCBChristopher BourneMMMegan M DacekEJElliott J Brea+1 more →
PMID: 31540894PMCID: PMC6891198DOI40 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
Cancer immunology research · 2019
DADavid A. ScheinbergMMMegan M DacekCYClaire Y OhCBChristopher BourneEJElliott J Brea+1 more →
PMID: 31540894PMCID: PMC6891198DOI40 citations
With Megan Dacek · Pharmacology (PhD) · Class of 2021
Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.
Oncoimmunology · 2019
DADavid A. ScheinbergCOClaire OhEJElliott J Brea
PMID: 31143508PMCID: PMC6527296DOI24 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019
Rejection of immunogenic tumor clones is limited by clonal fraction.
eLife · 2018
DADavid A. ScheinbergAYAaron Y ChangRSRon S GejmanHFHeather F JonesKDKrysta DiKun+1 more →
PMID: 30499773PMCID: PMC6269121DOI107 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
Rejection of immunogenic tumor clones is limited by clonal fraction.
eLife · 2018
DADavid A. ScheinbergHFHeather F JonesRSRon S GejmanAYAaron Y ChangKDKrysta DiKun+1 more →
PMID: 30499773PMCID: PMC6269121DOI107 citations
With Heather Jones · Pharmacology (PhD) · Class of 2022
CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.
Leukemia · 2017
DADavid A. ScheinbergAYA Y ChangMDM D Mathias
PMID: 28745331PMCID: PMC5628131DOI12 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
The Journal of clinical investigation · 2017
DADavid A. ScheinbergAYAaron Y ChangRSRon S GejmanLDLeonid DubrovskyMDMelissa D Mathias
PMID: 28628042PMCID: PMC5490756DOI79 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
JCI insight · 2017
DADavid A. ScheinbergAYAaron Y ChangEJElliott J BreaHWHans-Guido Wendel
PMID: 28352655PMCID: PMC5358483DOI40 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.
Oncoimmunology · 2016
DADavid A. ScheinbergCOClaire Oh
PMID: 28344864PMCID: PMC5353933DOI23 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.
Cancer immunology research · 2016
DADavid A. ScheinbergAYAaron Y ChangEJElliott J BreaCYClaire Y OhSBSadna Budhu+6 more →
PMID: 27680026PMCID: PMC5110210DOI154 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.
Cancer immunology research · 2016
DADavid A. ScheinbergCYClaire Y OhEJElliott J BreaSBSadna BudhuRSRon S Gejman+6 more →
PMID: 27680026PMCID: PMC5110210DOI154 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019
Opportunities and challenges for TCR mimic antibodies in cancer therapy.
Expert opinion on biological therapy · 2016
DADavid A. ScheinbergAYAaron Y ChangRSRon S GejmanEJElliott J BreaCYClaire Y Oh+1 more →
PMID: 27094818PMCID: PMC4936943DOI56 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
Opportunities and challenges for TCR mimic antibodies in cancer therapy.
Expert opinion on biological therapy · 2016
DADavid A. ScheinbergCYClaire Y OhAYAaron Y ChangRSRon S GejmanEJElliott J Brea+1 more →
PMID: 27094818PMCID: PMC4936943DOI56 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019
T cell receptor mimic antibodies for cancer therapy.
Oncoimmunology · 2015
DADavid A. ScheinbergAYAaron Y ChangLDLeonid DubrovskyRSRon S GejmanEJElliott J Brea+1 more →
PMID: 26942058PMCID: PMC4760335DOI41 citations
With Aaron Chang · Biochemistry & Structural Biology (PhD) · Class of 2018
T cell receptor mimic antibodies for cancer therapy.
Oncoimmunology · 2015
DADavid A. ScheinbergCYClaire Y OhLDLeonid DubrovskyRSRon S GejmanEJElliott J Brea+1 more →
PMID: 26942058PMCID: PMC4760335DOI41 citations
With Claire Oh · Pharmacology (PhD) · Class of 2019